Role of Drug-Induced Fas Ligand Expression in Breast Tumor Progression
Abstract
Fas/Fas ligand (FasL) is one of the key elements of the signaling pathway leading to cell death (apoptosis). It has been shown that FasL is overexpressed in some solid tumors and importantly, anticancer agents induce FasL expression in many tumor cell lines. Therefore, we have been using a mouse tumor model to investigate whether anticancer agents such as VP- 16 induce FasL expression in vivo and whether FasL expression promotes the growth of Fas deficient tumor cells. Preliminary data with mouse mammary tumor cells (CRL-21 16) support our hypothesis that anticancer drugs can induce FasL expression in vivo although more experiments are under way to confirm these results. To test the effect of drug-induced FasL expression on tumor growth, we will use CRL- 2116 cells to construct a stable Fasdef cell line that can be used as a negative control. Thus, we have cloned the wild-type mouse Fas and its dominant negative Fas mutant, and confirmed that both clones are expressed exogenousely. Once a stable Fasdef CRL-21 16 cell line is obtained, we will examine the effect of the drug- induced FasL on tumor growth of the Fasdef CRL-2 116 cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA387625
Entities
People
- William T. Beck
Organizations
- University of Illinois at Chicago